Modernatx, Inc.

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Massachusetts Institute of Technology

University of Massachusetts

Whitehead Institute for Biomedical Research

Moderna Therapeutics, Inc.

Alnylam Pharmaceuticals, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Whitehead Institute of Biomedical Technology

Europaisches Laboratorium Fur Molekularbiologie

Sayda Mahgoub Elbashir

Antonin De Fougerolles

Jason P Schrum

Thomas Tuschl

Winfried Lendeckel

Kristy M Wood

Tirtha Chakraborty

Stephane Bancel

Kenechi Ejebe

Jeff Lynn Ellsworth

Atanu Roy

Justin Guild

Paul Hatala

Susan Whoriskey

Matthias John

Giuseppe Ciaramella

Eric Yi-Chun Huang

Hans-Peter Vornlocher

Philipp Hadwiger

Sunny Himansu

Tal Zaks

Juergen Soutschek

Muthiah Manoharan

Rachel E Meyers

Gregory Sieczkiewicz

Kapil Bahl

Akshay Vaishnaw

Noubar Boghos Afeyan

Stephen G Hoge

Ron Weiss

Jens Harborth

Matthias Wilm

Saraswathy V Nochur

Paolo Lusso

Peng Zhang

Elisabeth Narayanan

Reinhard Lührmann

Gregory J Sieczkiewicz

Pedro Valencia

Reinhard LÜHRMANN

Saraswathy Nochur

Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.

Delivery and formulation of engineered nucleic acids

Provided herein are methods and compositions for inducing in a subject abroad neutralizing antibody response to human immunodeficiency virus (HIV) infection.

HIV RNA vaccines

Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.

Nucleic acid vaccines for varicella zoster virus (VZV)

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of long-lived polynucleotides, primary transcripts and mmRNA molecules.

Long-lived polynucleotide molecules

Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.

CHIKV RNA vaccines

The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.

Chikungunya virus RNA vaccines

The invention relates to a pharmaceutical composition including a plurality of lipid nanoparticles having a mean particle size of between 80 nm and 160 nm and containing an mRNA encoding a polypeptide. The lipid nanoparticles include a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. The mRNA contains a 5'-cap, 5&#x2032;-UTR, a 3&#x2032;-UTR, and a poly-A region with at least 100 nucleotides.

Modified Polynucleotides for the production of biologics and proteins associated with human disease

Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using ain vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3' ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.

RNA interference mediating small RNA molecules

Chikagunya virus RNA vaccines

Growing community of inventors

Cambridge, MA, United States of America

Sayda Mahgoub Elbashir